Document:

EX-10.16

 Exhibit 10.16 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 SUPPLY AGREEMENT 

THIS SUPPLY AGREEMENT (this “Agreement”) is made this, 14th day of April, 2014 (the “Effective
Date”), by and between HOVIONE INTER LTD., together with its subsidiaries and affiliates, a INTERSECT organized and existing under the laws of Switzerland and having its registered office at Bahnofstrasse 21, CH-600 Lucerne 7,
Switzerland (hereafter referred to as “HOVIONE”), and INTERSECT ENT, together with its subsidiaries and affiliates, a INTERSECT organized and existing under the laws of California and having its registered office at 1555 Adams
Drive, Menlo Park, CA 94025 (hereafter referred to as “INTERSECT”). HOVIONE and INTERSECT are each sometimes referred to herein as a “Party” and together as the “Parties.” 

WHEREAS, HOVIONE has developed and manufacturers the active pharmaceutical ingredient(s) identified in Exhibit A hereto (the
“API”); and 
 WHEREAS, INTERSECT developed and markets the Finished Product identified in Exhibit A based on the API, as
defined herein; and 
 WHEREAS, INTERSECT desires to acquire API from HOVIONE to incorporate into the Finished Product; and WHEREAS, HOVIONE
is willing to supply such API for INTERSECT’s use, on the terms and conditions set forth in this Agreement. 
 NOW THEREFORE, in
consideration of the promises and the mutual covenants set forth herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree and covenant as follows: 

1. Definitions. 
 1.1
“Active Pharmaceutical Ingredient” or “API” shall have the meaning given such term in the preamble hereof. 

1.2 “Affiliate” means any entity controlling, controlled by or under common control with either Party hereto.
For purpose of this definition “control” shall mean ownership of over fifty percent (50%) of the equity capital, the outstanding voting securities or other ownership interest of an entity, or the right to receive over fifty percent
(50%) of the profits or earnings of an entity. In the case of non-stock organizations, the term “control” shall mean the power to control the distribution of profits. 

1.3 “Applicable Law” shall mean the laws, regulations, rules and guidelines pertaining to the development,
manufacture, packaging, labeling, storage, import, export, distribution, marketing, sale and/or intended use of the API or the Finished Product. 

  
 1. 

 1.4 “Batch Record” shall mean a batch manufacturing record,
prepared according to applicable cGMP guidelines, for every production batch of API. 
 1.5 “Confidential
Information” shall mean all the technical information, whether tangible or intangible, including (without limitation) any and all data, techniques, discoveries, inventions, processes, know-how, patent applications, inventor certificates, trade
secrets, methods of production and other proprietary information, that either Party or its Affiliates have ownership rights to (as either owner, licensee or sub-licensee), or may hereafter obtain rights. 

1.6 “Current Good Manufacturing Practices” or “cGMP” shall mean current Good Manufacturing Practice as
set forth by the US FDA as well as current good manufacturing practices applicable to the API, or the making thereof at HOVJONE’s manufacturing facility, set forth by the relevant Regulatory Agency. 

1.7 “Defect” with respect to the API shall mean failure of the API to comply with the Product Specifications.

 1.8 “FDA shall mean the US Food and Drug Administration, and any successor thereto. 

1.9 “Finished Product” shall mean the finished dosage form combination drug and device product that contains the
API ready for commercial sale, as further described in Exhibit A hereto. 
 1.10 “Firm Forecast’’
shall have the meaning given to such term in Section 3.2 hereof. 
 1.11 “Product Specifications”
shall have the meaning given to such term in Section 2.2 hereof. 
 1.12 “Quality Agreement”
shall mean that certain Quality Assurance Agreement, dated of even date herewith, by and between INTERSECT and HOVIONE, which sets forth (a) the roles and responsibilities of the Parties with respect to the quality assurance for the API and
(b) how the Parties’ quality operations shall interact with each other in connection with the same. 
 1.13
“Regulatory Agency” shall mean national, or other government entities regulating or otherwise exercising authority with respect to the API or the Finished Product in the United States including, without limitation, the US FDA

 1.14 “Term” shall have the meaning assigned to such term in Section 10. 

2. Manufacture and Safe. 
 2.1
Supply. During the term of this Agreement and subject to the terms and conditions set forth herein, INTERSECT shall purchase a minimum of 80% of its annual API 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 2. 

 
requirement, from HOVIONE and HOVIONE shall manufacture and supply API to INTERSECT (or a third party designated by INTERSECT) in such quantities as from time to time may be ordered by INTERSECT.

 2.2 Product Specifications. The specifications of the API as set out in in Exhibit B to this Agreement (the “Product
Specifications”); as such Exhibit may be amended according to the terms of the quality agreement between the parties. 
 3. Costs. HOVIONE
shall be responsible for all costs and expenses related to the maintenance of a US DMF or European CEP for the API. Any additional submissions, technical work, documents, data or materials requested by INTERSECT may be chargeable by HOVIONE. 

4. Price, Orders and Terms of Payment. 

4.1 Pricing. The price for the API shall be as set forth on Exhibit C hereto. All sums shall be expressed in and payable in US Dollars.

 4.2 Forecasting. For each calendar year during the term of this Agreement, INTERSECT shall submit a twelve (12) month rolling
forecast updated on a quarterly basis, broken down on a quarterly basis covering INTERSECT’s anticipated requirements of API, each such forecast to be provided to HOVIONE at least ninety (90) days prior to the start of the relevant twelve
(12) month period. The rolling forecast shall be for information purposes only and non-binding so long as the INTERSECT provides a blanket purchase order covering their demand for the next six
(6) months. In the case that INTERSECT does not provide a blanket purchase order, the forecast will be considered binding. INTERSECT shall place all purchase orders with HOVIONE at least ninety (90) days in advance of required delivery to
INTERSECT. Within five (5) days of receipt of a purchase order, HOVIONE shall notify INTERSECT in writing of its acceptance of the purchase order and confirm the delivery date. If the purchase order exceeds the Firm Forecasted amount, HOVIONE
shall use commercially reasonable efforts to fill such order but shall not be in breach of this Agreement if HOVIONE does not supply the excess. 

4.3 Delivery Terms. Each purchase order shall specify: (i) an identification of the API ordered; (ii) quantity requested;
(iii) the requested delivery date; and (iv) shipping instructions and address. HOVIONE agrees to deliver the API DDP Palo Alto, CA USA (Incoterms 2010). 

4.4 Payment Terms. HOVIONE shall invoice INTERSECT upon dispatch of the API. INTERSECT shall pay the price to HOVIONE for API within
thirty (30) calendar days of the date of invoice of such API. Payments shall be made to HOVIONE by wire transfer. In case of delays on payment, INTERSECT agrees to pay interest on the outstanding amount at the prevailing Weighted Average Cost
of Capital (WACC) for Hovione on a monthly basis. 
 4.5 Scope of Agreement. In no event shall any terms or conditions included on
any purchase order, invoice or acknowledgement thereof or any other document, whether paper, electronic or otherwise, relating thereto, apply to the relationship between the Parties under this Agreement, unless such terms are expressly agreed to by
the Parties in writing. If there is a 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 3. 

 
conflict between the terms of any purchase order or other document and this Agreement, the terms of this agreement shall apply. The Parties further agree that no course of dealing between the
Parties shall in any way modify, change or supersede the terms and conditions of this Agreement. 
 5. Manufacture and Delivery of API. 

5.1 Manufacture. The API shall be manufactured by HOVIONE at its facilities in accordance with all relevant current Good Manufacturing
Practices (“cGMPs”), the Specifications, and Applicable Laws, , and pursuant to HOVIONE’s Drug Master File (“DMF”), prepared by HOVIONE and filed with the US FDA. HOVIONE shall advise INTERSECT in writing in
advance of making any changes to the Product Specifications or any material changes in the methods, processes or procedures in manufacturing the API that could affect the quality, purity and/or physical properties of the API, Any changes will be
made according to the terms of the quality agreement between the parties. HOVIONE shall provide sufficient notice of any such change to INTERSECT to allow INTERSECT to make any required notices to and obtain any required approvals from any
Regulatory Agency with respect to such change. 
 5.2 Right of Audit. INTERSECT and its representatives shall have the right to audit
HOVIONE for compliance with applicable regulatory requirements, including, but not limited to, cGMPs, at reasonable intervals and upon 30 days written notice. Such audits shall be scheduled at mutually agreeable times and shall not be more frequent
than once every three years. INTERSECT will also consider the use of an Rx-360 audit report as a substitute for conducting their own audit. 

5.3 Certificate of Analysis; Product Release. The quality control(s) and the release(s) of API (including documentation) shall be done
by HOVIONE in accordance with the Quality Agreement. HOVIONE shall provide certificates of analysis to INTERSECT for each batch of API delivered under this Agreement. API shall have at least [*] remaining on the date of delivery. 

5.4 Cooperation. During the term of this Agreement, HOVIONE shall assist and cooperate in a timely manner INTERSECT in its preparation
of any documents or other materials which may be required by the US FDA to validate sell and/or distribute the API to be supplied by HOVIONE under this Agreement or the Finished Product. HOVIONE shall file with the US FDA and shall maintain at all
times as current, a DMF for the API. HOVIONE shall also provide INTERSECT with a referral letter permitting INTERSECT to use HOVIONE’s DMF. 

5.5 Required Changes. INTERSECT shall deliver to HOVIONE written notice of any required changes to the Product Specifications requested
by the Regulatory Authorities, and HOVIONE shall use its commercially reasonable efforts to make such changes to the Product Specifications. If any change to Product Specifications requested by INTERSECT materially affects HOVIONE’s costs of
producing the API, then HOVIONE shall promptly so inform INTERSECT in writing and the Parties shall negotiate, in good faith, an adjustment to the pricing paid by INTERSECT for API under this Agreement. If the Parties cannot mutually agree,
following good faith negotiations, on an equitable adjustment to pricing, then either HOVIONE 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 4. 

 
or INTERSECT may terminate this Agreement for business reasons on not less than ninety (90) days prior written notice, without any further obligation to the other party; provided,
however, that INTERSECT shall remain liable for all sums owed to HOVIONE for orders of API that were placed prior to the date of termination 

5.6 Inspection of API. Within thirty (30) calendar days of the arrival of each lot of API at the manufacturing facility designated
by INTERSECT, INTERSECT shall inspect and test each lot of API at its own cost and expense. If, upon inspecting and testing the API, INTERSECT determines that a lot of API does not conform to the Product Specifications, then INTERSECT shall, within
such thirty (30) day period, give HOVIONE written notice of such non-conformity (setting forth the details of such non-conformity): Unless HOVIONE objects, within 20 working days from the notice by INTERSECT, to the non-conformity INTERSECT
will return the non-conforming API to HOVIONE. Any API rejected by INTERSECT may not be reshipped to INTERSECT except if the API is reprocessed according to the DMF. HOVIONE [*] replace any non-conforming API within thirty (30) days of
receiving the notice of non-conformity. Disputes between the Parties as to whether all or any part of a shipment rejected by INTERSECT materially conforms to the Product Specifications shall be resolved by a mutually acceptable third party testing
laboratory located in a neutral country. HOVIONE shall pay all the fees of the third party laboratory, unless the third party testing laboratory determines that the delivered API materially conforms to the Product Specifications, in which case
INTERSECT shall pay all the fees of such third party laboratory and also any additional costs that HOVIONE incurred in providing replacement material. 

5.7 Regulatory Communications. During the Term, HOVIONE shall notify INTERSECT after receipt of any communication from any Regulatory
Agency in connection or that can affect INTERSECT Marketing Authorisation. 
 5.8 Liability. It is understood that HOVIONE has no
control over the ultimate use of the Finished Product once it leaves INTERSECT’s manufacturing facility. HOVIONE shall have no liability arising out of or in connection with the sale or use of the API or any product or material made from or
incorporating the API, except to the extent that the API was not manufactured in accordance with the Product Specifications, cGMPs or Applicable Law or the liability otherwise arises from a breach of this Agreement by HOVIONE. 

5.9 Recall. INTERSECT shall be responsible for conducting any recall of Finished Product, and HOVIONE shall cooperate with and give all
reasonable assistance to INTERSECT in conducting any such recall to the extent it relates to the API. HOVIONE shall bear the expense of any recall resulting from a material breach of its obligations hereunder and/or of the Quality Agreement and/or
from its gross negligence or willful misconduct subject to the limits set out in 8.4. Otherwise, INTERSECT shall bear such expenses. In the event of such recall or similar action, each Party shall use commercially reasonable efforts to mitigate the
costs associated therewith. In the case of a disagreement as to the existence or level of nonconforming API, then the matter shall be referred to an independent third party laboratory. The decision of the laboratory shall be final and binding on the
Parties. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 5. 

 5.10 Retention of Documentation. All documentation related to the manufacturing of the API
shall be archived with HOVIONE after manufacturing in accordance with HOVIONE’s document retention policies. 
 5.11 Safety of
API. Each Party shall immediately notify the other Party of any unusual health or environmental occurrence relating to API . Each Party shall advise the other Party immediately of any safety or toxicity problems of which it becomes aware
regarding API. 
 6. Warranties. 
 6.1
HOVIONE’s Warranties. HOVIONE represents and warrants to INTERSECT that: 
 (a) It has full right and power to enter into this
Agreement and perform its obligations hereunder in accordance with its terms; 
 (b) The API and all components and ingredients thereof
shall be manufactured and delivered in strict compliance with: (i) the Product Specifications; (ii) the methods processes and procedures, including the site manufacture, set forth in the DMF, together with all applicable regulatory
requirements relating to the manufacture of the API 
 (c) the plant(s) for manufacture of the API is and shall be in compliance with all
applicable cGMPs and that such plant(s) is and shall continue to be available for inspection if and when the Regulatory Authorities so requests; 

6.2 INTERSECT’s Warranties. INTERSECT represents and warrants to HOVIONE that: 

(a) It has the full right and power to enter into this Agreement and perform its obligations hereunder in accordance with its terms; and 

(b) That it will purchase the API in strict compliance with the terms of this agreement. as set forth under Section 2.1 and 2.1 

6.3 Mutual Warranties. Each party represents and warrants to the other party that it holds all necessary and required permits and
authorizations, including, but not limited to, those required by the, and shall undertake throughout the term of this Agreement to maintain the same in full force and effect. Each party further covenants that it shall use commercially reasonable
efforts to obtain all such other permits and authorizations as may be reasonably required from time to time in either case to operate their respective facilities and/or businesses in order to manufacture, provide, distribute and/or sell API
hereunder. 
 7. Confidentiality. 
 7.1
Confidentiality. Each party agrees to retain in confidence all Confidential Information disclosed to it pursuant to this Agreement, whether such disclosure occurred before or after the date hereof. Disclosed information shall not be deemed
Confidential Information 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 6. 

 
hereunder if: (a) it is now or later becomes publicly known, other than through the fault of the receiving party; (b) it is lawfully known without restriction to the receiving party at
the time of disclosure as evidenced by written documentation; (c) it is rightfully obtained by the receiving party from a third party without restriction and without breach of this Agreement or any similar agreement; and/or (d) it is
independently developed by the receiving party without access to the disclosing party’s information, as evidenced by written documentation. If either Party is required under Applicable Law to disclose Confidential Information by any court or to
any Regulatory Agency, the Party required disclosing the Confidential Information shall, prior to such disclosure, notifying the other Party of such requirement and all particulars related to such requirement. The notified Party shall have the
right, at its expense, to object to such disclosure and to seek confidential treatment of any Confidential Information to be so disclosed on such terms as it shall determine, and the other Party shall fully cooperate with the notified Party in this
regard. The confidentiality of disclosed Confidential Information and the obligation of confidentiality hereunder shall survive any expiration or termination of this Agreement for a period of ten years. The Parties specifically agree that all terms
of this Agreement, all sales and API requirements and costs and all purchase orders shall be deemed to be confidential. 
 7.2 Separate
Confidentiality Agreement. If the Parties entered into one or more separate confidentiality agreements or non-disclosure agreements (each, a “Confidentiality Agreement”), such Confidentiality Agreement(s) shall be and remain in
full force and effect as provided therein. In the event of any conflict between the terms of this Agreement and the terms of any such Confidentiality Agreement, the terms of such Confidentiality Agreement shall control. 

7.3 Public Announcements. During the term of this Agreement, no party hereto shall issue or release, directly or indirectly, any press
release, marketing material or other communication to or for the media or the public that pertains to this Agreement, the API, the Finished Product or the transactions contemplated hereby (collectively, a “Press Release”) unless the
content of such Press Release has been approved by the other party hereto, such approval not to be unreasonably withheld or delayed; provided, however, that nothing contained in this Agreement shall prevent or preclude any party from
making such disclosures as may be required by applicable law, including, but not limited to, any disclosures required applicable securities laws. 
 8.
Indemnification. 
 8.1 INTERSECT shall indemnify, defend and hold HOVIONE and its officers, directors, affiliates, agents and
employees harmless from and against any and all claims, demands, costs, expenses, losses, liabilities and/or damages (including, but not limited to, reasonable attorneys’ fees) of every kind and nature caused by, arising out of or resulting
from INTERSECT’s negligence relating to, or breach of, this Agreement, and any claim for personal or bodily injury arising from the use of the Finished Product or any substance, dosage composition or compound manufactured therefrom;
provided, however, that in no event shall this Section apply to any claim covered by Section 8.2 below. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 7. 

 8.2 HOVIONE shall indemnify, defend and hold INTERSECT and its officers, directors, affiliates,
agents and employees harmless from and against any and all claims, demands, costs, expenses, losses, liabilities and/or damages (including, but not limited to, reasonable attorneys’ fees and court costs) of every kind and nature caused by,
arising out of or resulting from HOVIONE’s negligence relating to, or breach of, this Agreement and any claim for personal or bodily injury arising from the manufacture and/or distribution of API by HOVIONE. This indemnification obligation does
not apply to any claim for personal or bodily injury arising from the use or administration of the API except to the extent such injury is attributable to a Defect in the API arising out of HOVIONE’s gross negligence, willful misconduct, or
failure to manufacture and deliver the API in accordance with the Product Specifications and all Applicable Law. 
 8.3 Each party will
promptly notify the other of any actual or threatened judicial or other proceedings which could involve either or both parties. Each party reserves the right to defend itself in any such proceedings; provided, however, that, if
indemnity is sought, then the party from whom indemnity is sought shall have the right to control the defense of the claim, and the indemnified party may participate with counsel of its choice at its own expense. The Parties shall cooperate with
each other to the extent reasonably necessary in the defense of all actual or potential liability claims and in any other litigation relating to the API supplied pursuant to this Agreement. Each party will supply information to the other relevant to
any product liability claims and litigation affecting the API and/or the Finished Product, as the case may be. 
 8.4 NOTWITHSTANDING
ANYTHING IN THIS AGREEMENT TO THE CONTRARY, IN NO EVENT WILL EITHER PARTY BE LIABLE FOR ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR INDIRECT DAMAGES ARISING OUT OF THIS AGREEMENT, HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY. THIS LIMITATION WILL
APPLY EVEN IF THE OTHER PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGE; PROVIDED, HOWEVER, THAT THIS LIMITATION WILL NOT APPLY TO DAMAGES RESULTING FROM BREACHES BY A PARTY OF ITS DUTY OF CONFIDENTIALITY AND NON-USE IMPOSED
UNDER THIS AGREEMENT OR THE CONFIDENTIALITY AGREEMENT OR SUCH PARTY’S INDEMNIFICATION OBLIGATIONS STATED ABOVE. FURTHER AND NOTWITHSTANDING ANYTHING TO THE CONTRARY IN THIS AGREEMENT, THE [*] SHALL BE [*] OF THE [*]. 

9. Insurance. Unless the Parties otherwise agree in writing, the following terms shall apply: 

9.1 During the term of this Agreement and for a period [*] after any expiration or termination of this Agreement, each of INTERSECT and
HOVIONE shall maintain in full force and effect a comprehensive general liability insurance policy, including Products Liability coverage, with minimum limits of [*] for bodily injury including death. 

10. Term and Termination. 
 10.1
Term. 
 Unless terminated in accordance with the provisions of Section 10.2 below, the term of this Agreement shall commence on the Effective
Date and shall continue in effect for a FIVE (5) year period. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 8. 

 10.2 Grounds for Termination. 

(a) Either party shall have the right to terminate this Agreement upon the occurrence of any of the following events: (i) the failure of
the other party to comply with any of the terms of this Agreement or otherwise discharge its duties hereunder in any material respect, or the breach by the other party of any of its representations or warranties herein in any material respect, if
such failure or breach is not cured within ninety (90) days of such breaching party’s receipt of written notice specifying the nature of such failure or breach with particularity; or (ii) the making by the other party of an assignment
for the benefit of its creditors, or the filing by or against such other party of any petition under any federal, state or local bankruptcy, insolvency or similar laws, if such filing has not been stayed or dismissed within sixty (60) days
after the date thereof. 
 10.3 INTERSECT shall also have the right to suspend further performance under this Agreement and/or terminate
this Agreement in its entirety, without liability except for unpaid previously delivered API that conforms with the terms hereof, if: (i) HOVIONE loses any approval(s) from the US FDA required to perform its obligations under this Agreement or
if HOVIONE is involved in felonious or fraudulent activities; Continuing Obligations; Survival. In no event shall any termination or expiration of this Agreement excuse either party from any breach or violation of this Agreement and full
legal and equitable remedies shall remain available therefore, nor shall it excuse either party from making any payment due under this Agreement with respect to any period prior to the date of expiration or termination. 

11. Agreement to Consummate: Further Assurances. Subject to the terms and conditions of this Agreement, each of the Parties hereto agrees to use
commercially reasonable efforts to do all things necessary, proper or advisable under this Agreement, applicable laws and regulations to consummate and make effective the transactions contemplated hereby. If, at any time after the date hereof, any
further action is necessary, proper or advisable to carry out the purposes of this Agreement, then, as soon as is reasonably practicable, each party to this Agreement shall take, or cause its proper officers to take, such action. 

12. Force Majeure. Any delay in the performance of any of the duties or obligations of either party hereto (except for the payment of money) caused by
an event outside the affected party’s reasonable control shall not be considered a breach of this Agreement and the time required for performance shall be extended for a period equal to the period of such delay. Such events shall include, but
will not be limited to, acts of God, acts of a public enemy, acts of terrorism, insurrections, riots, injunctions, embargoes, fires, explosions, floods, or other unforeseeable causes beyond the reasonable control and without the fault or negligence
of the Party so affected. The Party so affected shall give prompt written notice to the other party of such event. The suspension of performance shall be of no greater scope and no longer duration than is reasonably required and the nonperforming
Party shall use its commercially reasonable efforts to remedy its inability to perform; provided, however, that in the event the suspension of performance continues for sixty (60) days after the date of the occurrence, and such failure to
perform would constitute a material breach of this Agreement in the absence of such force majeure event, the no affected Party may terminate this Agreement immediately by written notice to the affected Party. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 9. 

 13. General Provisions. 

13.1 Assignment. Neither this Agreement nor any interest herein may be assigned, in whole or in part, by either party without the prior
written consent of the other, which consent shall not be unreasonably withheld or delayed, except that either party may assign its rights and obligations under this Agreement: (a) to an affiliate, division or subsidiary of such party; and/or
(b) to any third party that acquires all or substantially all of the stock or assets of such party, whether by asset sale, stock sale, merger or otherwise, and, in any such event such assignee shall assume the transferring party’s
obligations hereunder. However, notwithstanding any such assignment, in the case of an assignment to an affiliate, division or subsidiary, the transferring party shall remain liable under this Agreement (in addition to the transferee) unless such
liability is specifically waived in writing by the other party hereto. Subject to the foregoing, this Agreement shall be binding upon and inure to the benefit of the Parties hereto, and their respective successors and permitted assigns. 

(a) Buyout. In the case that either company is acquired by, or merges with, another company which has reason to not wish to continue
the relationship, that company may make a contract buyout payment [*] for the [*], with a [*] buyout payment amount of [*]. 
 13.2
Notice. Any notice or request required or permitted to be given under or in connection with this Agreement shall be deemed to have been sufficiently given if in writing and sent by: (a) personal delivery against a signed receipt
therefore, (b) certified mail, return receipt requested, first class postage prepaid, (c) nationally recognized overnight delivery service (signature required), (d) confirmed facsimile transmission, or (e) electronic mail (with
any notices to sent by facsimile transmission or electronic mail to also be sent by one of the other methods set forth in this Section), addressed as follows: 
  

			
	If to HOVIONE, then to:	  	  

		  	Attention:
                                         
                                         
    
		  	Facsimile: (        )          -         
		
	With a copy, sent as provided herein, to:	  	  

		  	Attention:
                                         
                                         
     
		  	Facsimile: (        )          -         
		
	If to INTERSECT, then to:	  	 1555 Adams Dr., Menlo Park, CA 94025

		  	Attention:         Felicia Mercado            
		  	Facsimile: (650) 641-2137
		
	With a copy, sent as provided herein, to:	  	 1555 Adams Dr., Menlo Park, CA 94025

		  	Attention:         Dan Castro                
		  	Facsimile: (650) 641-2117

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 10. 

 Any party may alter the address to which communications are to be sent by giving notice of such change of address
in conformity with the provisions of this Section providing for the giving of notice. Notice shall be deemed to be effective, if personally delivered, when delivered; if mailed, at midnight on the third business day after being sent by certified
mail; if sent by nationally recognized overnight delivery service, on the next business day following delivery to such delivery service; and if sent by confirmed facsimile transmission or electronic mail, on the next business day following
transmission (so long as any notices sent by facsimile transmission or electronic mail are also sent by one of the other methods set forth in this Section). 

13.3 Entire Agreement. This Agreement sets forth the entire agreement and understanding between the Parties as to the subject matter
hereof and merges all prior discussions and negotiations between them, and neither party shall be bound by any conditions, definitions, warranties, understandings or representations with respect to such subject matter other than as expressly
provided herein or as duly set forth on or subsequent to the date hereof in writing and signed by a proper and duly authorized officer or representative of the Parties to be bound thereby, except that this Agreement shall not supersede any separate
confidentiality or non-disclosure agreement that may have been, or that may be, entered into by the Parties. To the extent that any conflict arises among the documents that comprise this Agreement (including any schedules or exhibits), the terms and
conditions of this Agreement shall govern. The terms and conditions of this Agreement shall control over and supersede any contrary term in any purchase order. 

13.4 Amendment and Modification. This Agreement may be amended, modified and supplemented only by written agreement duly executed and
delivered by each of the Parties hereto. 
 13.5 Waiver. The failure of any party to exercise any right or to demand the performance
by the other party of duties required hereunder shall not constitute a waiver of any rights or obligations of the Parties under this Agreement. A waiver by any party of a breach of any of the terms of this Agreement by any other party shall not be
deemed a waiver of any subsequent breach of the terms of this Agreement. 
 13.6 Governing Law. This Agreement is to be governed by
and construed in accordance with the laws of the State of New York, United States, notwithstanding any conflict of law provisions to the contrary. The United Nations Convention on Contracts for the International Sale of Goods shall not apply to this
Agreement. Any action which in any way involves the rights, duties and obligations of either party hereto under this Agreement shall be brought in the courts of Geneva and the Parties to this Agreement hereby submit to the personal jurisdiction of
any such court. The Parties waive any and all rights to have any dispute, claim or controversy arising out of or relating to this Agreement tried before a jury. 

13.7 Severability. Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid
under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any
other provision of this Agreement or any action in any other jurisdiction, but this Agreement shall be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision had not been contained herein. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 11. 

 13.8 Construction. The Parties have participated jointly in the negotiation and drafting
of this Agreement. In the event of any ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the Parties and no presumption or burden of proof shall arise favoring or disfavoring any
party by virtue of the authorship of any of the provisions of this Agreement. As used in this Agreement, the singular shall include the plural and vice versa, and the terms “include” and “including” shall be deemed to be
immediately followed by the phrase “but not limited to.” The terms “herein” and “hereunder” and similar terms shall be interpreted to refer to this entire Agreement, including any schedules attached hereto. 

13.9 Parties/Relationship. Neither party shall hold itself out to third parties as possessing any power or authority to enter into any
contract or commitment on behalf of any other party. This Agreement is not intended to, and shall not; create any agency, partnership or joint venture relationship between or among the Parties. Each Party is an independent contractor with respect to
the others. No Party is granted any right or authority to assume or create any obligation or responsibility, express or implied, on behalf of, or in the name of any other Party hereto, or to bind any other party hereto in any manner or with respect
to anything, whatsoever. 
 13.10 Captions. The captions and headings in this Agreement are inserted for convenience and reference
only and in no way define or limit the scope or content of this Agreement and shall not affect the interpretation of its provisions. 

13.11 Counterparts. This Agreement may be executed in multiple counterparts, each of which shall be deemed an original and all of which
together shall constitute one and the same instrument. 
 13.12 Subcontractors. Any work that is to be done by any Party under this
Agreement may be subcontracted to a third party in accordance with the approved Marketing Authorisation, cGMPs and any applicable PMDA guidelines which relate to the work to be performed under the direction and supervision of such party, as the case
may be; provided, however, that the subcontracting party exercises reasonable diligence in selecting such subcontractor and, as between the parties hereto, the subcontracting party shall be and remain responsible for all acts and omissions of any
such subcontractor. 
 13.13 Schedules and Exhibits. All Schedules and Exhibits referenced in this Agreement, if any, are hereby
incorporated by reference into, and made a part of, this Agreement. 
 13.14 Currency. All sums set forth in this Agreement and ay
appendices, exhibits or schedules hereto are, and are intended to be, expressed in US dollars. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 12. 

 IN WITNESS WHEREOF, the parties have executed the Agreement as of the date first above written. 

 

									
	HOVIONE Inter Ltd:	 		 	INTERSECT:
			
	  
	 		 	
					
	By:	 	 /s/ David Hoffman
	 		 	By:	 	 /s/ NK

									
					
	Name:	 	David Hoffman	 		 	Name:	 	Richard Kaufman
		 	            (Print/Type)	 		 		 	

									
			
	Its: VP Sales and Business Development	 		 	Its: Chief Operating Officer
			
	Date: 14th April 2014	 		 	Date: 4/14/14

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 13. 

 EXHIBIT A 

API 
 Mometasone Furoate
Anhydrous, Micronized 
 Finished Products 

Propel®Propel Mini ® 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 1 

 EXHIBIT B 

Product Specifications 
 Reference Intersect ENT
part specification: 00002 MOMETASONE FUROATE. Most recent copy of specification shall be submitted with applicable purchase order. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 1 

 EXHIBIT C 

Pricing 
  

			
	(a)	  	Current API pricing is established at $[*]/gram.
		
	(b)	  	The following tiered pricing applies to future annual demand volumes:
		
	(i)	  	[*] grams: $[*]/gram
		
	(ii)	  	[*] grams: $[*]/gram
		
	(iii)	  	[*] grams: $[*]/gram
		
	(iv)	  	[*] grams: $[*]/gram

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 1EX-10.17

 Exhibit 10.17 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 SUPPLY AGREEMENT 

THIS SUPPLY AGREEMENT (the “Agreement”) is made and entered into as of
[January 28, 2014] (the “Effective Date”) by and between Intersect ENT, Inc., a Delaware corporation having offices at 1555 Adams Drive, Menlo Park, CA 94025 (“Customer”), and [AIM Plastics], a Michigan
corporation having offices at 22264 Starks Drive Clintontownship, MI 48036 (“Supplier”). Each of Customer and Supplier may be referred to herein individually as a “Party” and collectively as the
“Parties”. 
 RECITALS 

WHEREAS, Customer wishes to engage Supplier to manufacture and supply to Customer certain products, in accordance with all applicable laws and
regulations; and 
 WHEREAS, Supplier is willing to supply Customer such products pursuant to the terms and conditions as set forth herein.

 NOW, THEREFORE, in consideration of the foregoing and the covenants and promises contained in this Agreement, Customer and Supplier
hereby agree as follows: 
 ARTICLE 1 

DEFINITIONS 
 1.1
“Affiliate” means, with respect to a Party, any corporation or other business entity controlling, controlled by or under common control with such Party. The term “controlling” (with correlative meanings for the terms
“controlled by” and “under common control with”) as used in this definition means either (a) possession of the direct or indirect ownership of more than fifty percent (50%) of the voting or income interest of the
applicable corporation or other business entity, or (b) the ability, by contract or otherwise, to control the management of the applicable corporation or other business entity.  

1.2 “Certificate of Analysis” has the meaning set forth in Section 3.4. 

1.3 “Certificate of Compliance” has the meaning set forth in Section 3.4. 

1.4 “Change of Control” means, with respect to a Party: (a) the sale of all or substantially all of such Party’s
assets; (b) a merger or consolidation involving such Party in which the voting securities of such Party outstanding immediately prior thereto cease to represent at least fifty percent (50%) of the combined voting power of the surviving
entity immediately after such merger or consolidation; or (c) a person or entity, or group of persons or entities, acting in concert (other than a trustee or other fiduciary holding securities under an employee benefit plan) acquire more than
fifty percent (50%) of the voting equity securities or management control of such Party. Notwithstanding the foregoing, a financing transaction in which fifty percent (50%) or more of the voting control of a Party is transferred to one or
more Third Parties in connection with the financing or refinancing of the business of such Party does not constitute a Change of Control. 

 1.5 Confidential Information” means each Party’s confidential information,
inventions, know-how or data disclosed pursuant to this Agreement, which may include, without limitation, manufacturing, marketing, financial, personnel and other business information and plans, whether in oral, written, graphic or electronic form.
 
 1.6 “Customer Change Order” has the meaning set forth in Section 4.2(b). 

1.7 “Defective Product” has the meaning set forth in Section 3.6(a). 

1.8 “FDA” means the United States Food and Drug Administration, or any successor thereto. 

1.9 “FD&C Act” means the United States Federal Food, Drug and Cosmetic Act, as amended, and any regulations promulgated
thereunder. 
 1.10 “Forecast” has the meaning set forth in Section 2.2. 

1.11 “GMP” means the then-current good manufacturing practice and standards, as set forth in the FD&C Act, as amended,
and applicable regulations and guidances promulgated thereunder, including without limitation 21 CFR §§210-211.  
 1.12
“Inventions” has the meaning set forth in Section 9.3. 
 1.13 “Lead Time” means eight (8) weeks, or
such other period of time that the Parties mutually agree in writing is the minimum period required by Supplier to deliver a given type of Product hereunder, measured from the date of Supplier’s receipt of a purchase order. Initial kanban
delivery shall be within the Lead Time. All subsequent releases shall be delivered within forty-eight (48) hours of request by Customer. 

1.14 “Product” means any of the products listed on Exhibit A attached hereto, as such list may be amended from time to time
by mutual written agreement of the Parties. 
 1.15 “Quality Control Procedures” has the meaning set forth in
Section 3.1. 
 1.16 “Regulatory Standards” has the meaning set forth in Section 3.1. 

1.17 “Specifications” shall mean the formula(s), stability, and other product characteristics, and the manufacturing,
processing, labeling, storage, and packaging requirements and standards, in each case pertaining to a particular Product, as such are set forth in Exhibit B, as the same may be amended or supplemented from time to time pursuant to Section 4.2
or by mutual written agreement of the Parties. 
 1.18 “Third Party” means any entity or individual other than the
Parties and their respective Affiliates. 
 ARTICLE 2 

SUPPLY OBLIGATIONS 

2.1 Manufacture and Supply. Supplier agrees to manufacture and supply to Customer the quantities of each Product set forth on purchase
orders submitted from time to time by Customer in accordance with the provisions of Section 2.3. Any purchase orders for Product submitted by Customer shall reference this Agreement and shall be governed exclusively by the terms contained
herein. Any  

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
term or condition in any purchase order, confirmation, or other document furnished by Customer or Supplier that is in any way inconsistent with the terms and conditions set forth in this
Agreement is hereby expressly rejected. 
 2.2 Forecasts. On or before the first day of each calendar quarter, Customer will provide
Supplier with a rolling forecast based on its best current understanding of its expected orders of each of the Products for each of the following twelve (12) months (each, a “Forecast”). The first three (3) months of each
such Forecast will constitute a binding commitment by Customer to place Purchase Orders, during such three (3) month period, ordering at least the total amount of each Product as set forth in such Forecast, and Supplier will be obligated to
supply to Customer one hundred percent (100%) of the quantities of such binding commitments as ordered; the remaining nine (9) months will be non-binding and solely for planning purposes. 

2.3 Orders. From time to time during the term of this Agreement, Customer may provide to Supplier a written purchase order for one or
more Products, which shall specify: (a) the name, part number, and quantity of each Product ordered; (b) the unit price of each Product ordered and the total purchase price; (c) the required delivery date(s); (d) the billing and
shipping address(es); and (e) any special instructions or other pertinent requirements. Customer may submit purchase orders by mail, facsimile or email. Within three (3) business days after its receipt of a purchase order placed pursuant
to this Section 2.3, Supplier shall notify Customer of its acceptance or rejection (including reasons for rejection). If within such time period Supplier does not provide notice of acceptance or rejection to Customer, then the purchase order
shall be deemed to be accepted. Supplier shall not be permitted to reject any purchase order unless such purchase order specifies a delivery date for a Product that is not consistent with the applicable Lead Time for such Product or is for
quantities of Product in excess of [*] of amount in the binding portion of the most recent Forecast. 
 2.4 Cancellation. Customer
may cancel any purchase order by providing written notice to Supplier no later than ten (10) days prior to the delivery date specified therein. Customer shall be required to pay for any costs incurred by Supplier with respect to a purchased raw
material specific to the cancelled PO plus any parts in WIP and finished goods at the time of order cancellation. 
 2.5 Inventory.
Supplier shall maintain at all times an inventory of each Product equal to Customer’s three (3) month requirements of such Product, where such requirements shall be determined based on the current Forecast described in Section 2.2.
Supplier will fulfill purchase orders for Products submitted by Customer out of such inventory on a “first in, first out” basis (and will accordingly replace the consumed inventory on a timely basis). Supplier will be responsible for such
inventory of Products until ownership of particular quantity of Product is transferred to Customer based on fulfillment of a purchase order in accordance with the delivery terms of this Agreement. Supplier will maintain adequate inventories of all
starting materials needed to fulfill its obligations to manufacture and supply Products under this Agreement during the binding and non-binding Forecast periods. 

2.6 Delivery. Supplier shall deliver to Customer or its designee, at the delivery destination and by the delivery date specified in the
applicable purchase order, the specified quantity of each Product conforming with the Specifications and that has been manufactured in accordance with the Quality Control Procedures and the other requirements set forth in this Agreement. Time is of
the essence with respect to delivery of Products by Supplier under this Agreement. Supplier shall promptly notify Customer of any actual or prospective delay in delivery and shall obtain Customer’s approval prior to making any partial
deliveries. If the delivery of any Product under a purchase order is delayed through no fault of Customer, then Customer may, at its option, in addition to its other available remedies, cancel or reschedule the order in whole or in part, without
liability to Supplier. If necessary for Supplier to meet its delivery requirements, Supplier, at its expense, will use expedited delivery methods to complete and 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
deliver the ordered Products. All Products delivered hereunder will be accompanied by the following documentation: (a) the batch number and order number of the delivered Products;
(b) the applicable batch manufacturing records and a summary of deviations; (c) a Certificate of Analysis and Certificate of Compliance, as described in Section 3.3; and (d) any other documentation that Supplier customarily
includes in shipments of such Products or that Supplier is required to include by applicable laws or regulations. 
 2.7 Shipping.
All shipments will be made FCA (Incoterms 2010) Supplier’s facility. All Products manufactured by Supplier shall be packaged in accordance with the Specifications. 

2.8 Shortfalls in Supply. 

(a) Should either Party perceive that a shortfall in delivery of Products by Supplier is likely to occur for any reason, such Party
shall promptly notify the other Party, and the Parties shall discuss in good faith appropriate steps to alleviate such a shortfall. 

(b) If Supplier fails to deliver any Products at the time and place set forth in the applicable purchase order submitted under
Section 2.3, Supplier shall use best efforts to cure such failure, and Customer shall have the right, at its sole option, to take any or all of the following actions: (i) require Supplier to use expedited delivery methods to complete and
deliver some or all of the relevant Products; (ii) allocate or redirect some or all of the relevant Products to one or more destinations specified by Customer; (iii) cancel all or any part of the corresponding purchase order. Supplier will
review pricing annually and extend all price reductions available. 
 2.9 Product Discontinuance. Supplier shall not discontinue any
Product during the Initial Term (as defined in Section 10.1). Thereafter, Supplier may discontinue a Product upon twelve (12) months written notice to Customer. Customer shall have the right to place a last time buy order for the
discontinued Product in accordance with Section 10.6, and Supplier shall accept such order at the price in effect as of its notice of discontinuation, except that Supplier shall also pass on to Customer any savings in connection with increased
volumes ordered. 
 ARTICLE 3 

QUALITY CONTROL; ACCEPTANCE AND REJECTION 

3.1 Quality Control. Supplier shall maintain and follow, and shall ensure that any Third Parties responsible for the manufacture and/or
supply of raw materials or components for Products maintain and follow, a quality control and testing program consistent with GMP and prevailing industry standards (the “Quality Control Procedures”). All Products supplied hereunder
shall be manufactured in accordance with the Quality Control Procedures and all applicable requirements of regulatory authorities, including GMP (collectively, “Regulatory Standards”). Supplier shall maintain all quality control
documentation for each lot of Products for a period of three (3) years after Supplier delivers such Product to Customer or its designee. During the term of this Agreement, Customer may periodically review such documentation and results, and
shall have the right to audit, survey, or verify the adherence of Supplier to the Quality Control Procedures, Regulatory Standards and this Agreement. Upon written request to Supplier, Customer shall have the right to have its representatives or
representatives of regulatory authorities visit the manufacturing facilities of Supplier during normal business hours to review Supplier’s manufacturing operations and records, to assess its compliance with the Quality Control Procedures,
Regulatory Standards and this Agreement, and to discuss any related issues with Supplier’s manufacturing and management personnel. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 3.2 Quality Agreement. The responsibilities of the quality units of each Party related to
the manufacture of Products are described in that certain Quality Agreement between the Parties dated [October 2013] (the “Quality Agreement”). Supplier will comply with the terms of the Quality Agreement in conducting its
activities under this Agreement. 
 3.3 Regulatory Inspection. Supplier shall notify Customer within twenty-four (24) hours of
any written or oral inquiries, notifications or inspection activity by any regulatory authority or other governmental agency or authority of competent jurisdiction in regard to Products to be supplied to Customer hereunder (including inspection with
respect to International Standards Organization standards). Supplier will permit a representative of Customer to be present during such an inspection. Supplier will provide a reasonable description of any such governmental inquiries, notifications
or inspections promptly, but in no event later than two (2) business days, after such notification, inquiry or inspection. Supplier will furnish to Customer (i) within two (2) business days after receipt, any report or correspondence
issued by any regulatory authority in connection with such notification, inquiry or inspection to the extent relevant to any Product, and (ii) copies of proposed responses or explanations. Prior to responding, Supplier will discuss the proposed
response with Customer and will implement in good faith any comments provided by Customer relating to a Product. 
 3.4 Certificates.
Each batch of any Product delivered to Customer shall be accompanied by (i) a written certificate of analysis confirming that each unit of such Product in such batch has been tested in accordance with the mutual agreed acceptance tests and
conforms to the Specifications (“Certificate of Analysis”) and (ii) a written certificate of compliance confirming that the Product was manufactured in accordance with Regulatory Standards (“Certificate of
Compliance”). Customer may then retest the batch of Product to confirm that it meets the Specifications. 
 3.5
Notifications. Supplier shall notify Customer immediately upon becoming aware of: (a) any defect or condition that renders or may render any Product ineffective or dangerous; (b) any Product that is not in compliance with the
Specification or any Regulatory Standards; (c) any breach by Supplier of this Agreement; or (d) infringement by any Third Party of any intellectual property rights related to any Product. 

3.6 Acceptance and Rejection. 

(a) Customer may reject any Product delivered under this Agreement that does not comply with the warranties set forth in
Section 6.3 (a “Defective Product”) by giving written notice of such Defective Product to Supplier within forty-five (45) days after receipt thereof. Customer shall be entitled to reject all or a portion of an entire lot
or shipment of a Product if a tested sample of that lot or shipment contains any Defective Products. Acceptance of Products by Customer shall not limit Customer’s rights under Section 7.1. 

(b) If, after Customer’s initial acceptance, Customer discovers that such Product is a Defective Product and that the nature of
such defect likely could not have been discovered through the exercise of reasonable diligence within forty-five (45) days of Customer’s receipt of such product, Customer may revoke its acceptance of such Defective Product by providing
written notice to Supplier of such revocation. 
 (c) Customer shall return Defective Products to Supplier at Supplier’s
expense. With respect to Defective Products that have been properly rejected pursuant to Section 3.6(a) or 3.6(b), Customer shall not be required to pay for such Defective Products under Section 5.1. Supplier shall replace such Defective
Products as quickly as possible, and Customer shall pay Supplier for such replacement Product in accordance with Section 5.1, or in the event that Customer has already paid for the Defective Products, Supplier shall replace such Defective
Products at its own expense. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 (d) If, after Customer rejects any Defective Product, Supplier fails to promptly replace
such Defective Product, then Customer shall have the right, upon notice to Supplier, to cancel the applicable purchase order relative to the rejected Products without penalty and require refund of any payments made relative to the rejected Products.

 (e) If Supplier disagrees with Customer’s determination that certain units of Product are Defective Product, the Parties will
first use good faith efforts to settle such dispute within forty-five (45) days of Customer’s notice of such alleged defects. If the Parties are unable to resolve such dispute within this forty-five (45) day period, such Product shall
be submitted to a mutually acceptable Third Party testing service. Such Third Party testing service shall determine whether such Product meets the Specifications, and the Parties agree that such testing service’s determination shall be final
and binding on the Parties. The Party against whom the Third Party laboratory rules shall bear all costs of the Third Party testing. 

ARTICLE 4 
 OTHER
AGREEMENTS OF THE PARTIES 
 4.1 Regulatory Assistance. Supplier shall provide all regulatory and technical information relating
to the manufacture and supply of the Products as reasonably requested by Customer, and shall otherwise use commercially reasonable efforts to assist Customer, in each case in connection with obtaining any regulatory approvals with respect to
Customer products incorporating Products. Supplier shall notify Customer promptly in writing in the event any action is taken or threatened by a regulatory authority relating to the manufacture or storage of Product, or relating to the Supplier
facility in which such manufacture or storage occurs, or which may impair the ability of Supplier to supply Product in accordance with this Agreement. 

4.2 Changes. 

(a) Supplier shall not change the Specifications for a Product or change the materials, equipment, process or procedures used to
manufacture or test Product in a manner that (i) would be inconsistent with the Specifications, (ii) would affect the form, fit, function, performance, or stability of a Product, or (iii) would require regulatory approval. 

(b) If Customer finds it necessary or desirable to change Specifications for any Product, Customer may deliver a request for such
change to Supplier (“Customer Change Order”). Within fifteen (15) days of Customer’s delivery of a Customer Change Order, Supplier shall provide Customer with a written quotation containing the proposed increase or
decrease in the unit price of the Products as a result of implementing such Customer Change Order, if any. The Parties shall make a good faith effort to agree upon any such increase or decrease as soon as reasonably practicable. Once the Parties
have agreed upon any resulting unit price change, Supplier shall incorporate the proposed engineering change into the Products on a schedule to be agreed to by the Parties. Supplier shall not proceed to implement any Customer Change Order without
Customer’s written authorization. 
 4.3 Raw Materials and Components. During the term of this Agreement, Supplier shall be
solely responsible for obtaining, and shall store at no cost to Customer, any and all raw materials or components required for the manufacture of the Products, in reasonable quantities consistent with Customer’s Forecasts and purchase orders.
Supplier will ensure that all Third Parties responsible for the  

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
manufacture and/or supply of raw materials or components for Products have entered into an agreement with Supplier obligating such Third Parties to comply with all applicable Specifications,
quality standards, and other technical requirements that may be necessary in order for the such Third Parties to timely deliver conforming Product, or any portion thereof, to Supplier for the benefit of Customer. Supplier may not change Third Party
sources without written consent of Customer. 
 4.4 Compliance with Laws. All Product supplied to Customer hereunder shall be
manufactured in compliance with all applicable present and future orders, regulations, requirements and laws of any and all federal, state, provincial and local authorities and agencies, including without limitation all laws and regulations of such
territories applicable to the transportation, storage, use, handling and disposal of hazardous materials. Supplier represents and warrants to Customer that Supplier shall obtain and maintain all site licenses and government permits, including
without limitation health, safety and environmental permits, necessary for the conduct of the actions and procedures undertaken to supply Product during the term of this Agreement. Upon Customer’s request, Supplier shall promptly provide a copy
of such licenses and permits. 
 4.5 Records. Supplier shall keep, or cause to be kept, complete, accurate and authentic
accounts, notes, data and records pertaining to the manufacture, processing, testing, labeling, storage, and distribution of Products sold to Customer, including without limitation master production and control records, in accordance with applicable
laws and regulations. Supplier shall retain, or cause to be retained, such records for a period of three (3) years following the date of manufacture, or longer if required by law, and upon request, shall make available to Customer copies of
such records. After such time period, Supplier shall notify Customer prior to the destruction of any records retained under this Section 4.5 and, at Customer’s request, shall provide such records to Customer. 

4.6 Rework. Supplier shall not rework any batch of any Product without Customer’s prior written consent, which consent shall not
be unreasonably withheld. 
 ARTICLE 5 

PRICES AND PAYMENT 

5.1 Price. The purchase prices for Products ordered during the term of this Agreement are set forth in Exhibit A; provided, however,
that Supplier may reduce the purchase price of any Product at any time. Supplier agrees, upon request by Customer, to negotiate in good faith reductions in the purchase prices as necessary to respond to market and competitive conditions. In
addition, Supplier shall use commercially reasonable efforts to reduce its costs for each Product and shall decrease the prices for Products so that Customer receives the benefit of any such cost reduction. Such price reduction shall take effect no
later than thirty (30) days after the corresponding reduction in Supplier’s costs and will not be retroactive. Reductions in the purchase price of any Product shall apply to any purchase orders for which delivery of Products has not yet
occurred. Cost reduction efforts shall not compromise the quality or reliability of any Product, and Supplier shall comply with the Quality Agreement with respect to design and process changes. 

5.2 Invoice and Payment. Supplier shall provide to Customer a written invoice for each shipment of Product delivered to Customer or its
designee. Unless otherwise stated in Exhibit A, all payments due hereunder to Supplier shall be made not later than forty-five (45) days following the later of (a) Customer’s receipt of the applicable invoice or
(b) Customer’s receipt and acceptance of the relevant batch of Product at its destination. All payments hereunder shall be in United States dollars. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 5.3 Offset. Customer may offset and deduct from amounts due from Customer to Supplier any
amounts due from Supplier to Customer. 
 5.4 Taxes. Customer will pay any applicable sales, use or similar tax imposed in
connection with the sale of Products to Customer hereunder; provided, that Supplier shall not charge or collect, and Customer shall have no liability for, taxes on any sale of Products for which Customer has provided Supplier with an appropriate
resale certificate or other documentation evidencing an exemption from such taxes. For all sales of Products upon which tax reimbursement to Supplier is applicable, Supplier shall separately identify and itemize all applicable taxes on invoices
submitted to Customer. 
 5.5 Most Favored Customer. The purchase prices for the Products are and will continue to be the
lowest prices charged by Supplier for the same or substantially similar products. If at any time during the term of this Agreement, Supplier offers or sells the same or substantially similar products to a Third Party at a lower price than the prices
set forth herein, Supplier will immediately notify Customer and reduce the purchase prices for the applicable Products to such lower price on any pending and future purchase orders for the Products hereunder. 

ARTICLE 6 

REPRESENTATIONS AND WARRANTIES 

6.1 Mutual Representations and Warranties. Each Party hereby represents and warrants to the other Party as follows, as of the Effective
Date: 
 (a) Corporate Existence and Power. It is a corporation or other entity duly organized, validly existing, and in good
standing under the laws of the jurisdiction in which it is incorporated or established, and has full corporate power and authority and the legal right to own and operate its property and assets and to carry on its business as it is now being
conducted and as contemplated in this Agreement. 
 (b) Authority and Binding Agreement. It has the corporate power and authority and
the legal right to enter into this Agreement and perform its obligations hereunder; it has taken all necessary corporate action on its part required to authorize the execution and delivery of the Agreement and the performance of its obligations
hereunder; and the Agreement has been duly executed and delivered on behalf of such Party, and constitutes a legal, valid, and binding obligation of such Party that is enforceable against it in accordance with its terms. 

(c) No Conflict. The execution and delivery of this Agreement and the performance of its obligations hereunder (i) do not conflict
with or violate any requirement of applicable laws or regulations and (ii) do not conflict with, or constitute a default or require any consent under, any of its contractual obligations. 

6.2 Representations and Warranties of Supplier. Supplier represents and warrants to Customer that: 

(a) Supplier has not been debarred by the FDA or other regulatory authority, and has not been convicted of a crime that could lead to
such debarment, and no person or entity that has been debarred by the FDA or other regulatory authority, or, to the best of Supplier’s knowledge, is the subject of debarment proceedings by the FDA or other regulatory authority, will be involved
in the performance of Supplier’s obligations under this Agreement. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 (b) Supplier is in full compliance with (i) any and all quality control standards
that are referenced in the Specifications and (ii) any and all Customer standard operating procedures that have been provided to Supplier, and Supplier agrees to inform Customer immediately regarding any change in this status. 

(c) Supplier shall not enter into any agreement or arrangement with any other entity that would prevent or in any way interfere with
Supplier’s ability to perform its obligations pursuant to this Agreement. 
 6.3 Product Warranty. Supplier warrants that all
Products manufactured hereunder will (i) conform to the applicable Specifications; (ii) be manufactured and released in compliance with the Quality Control Procedures and Regulatory Standards; (iii) not be adulterated or misbranded
within the meaning of the FD&C Act; (iv) be free and clear of any and all encumbrances, liens, or other Third Party claims; and (v) not infringe or misappropriate the intellectual property rights of any Third Party. 

ARTICLE 7 

INDEMNIFICATION 
 7.1
Supplier Indemnity. Supplier shall indemnify, hold harmless, and defend Customer and its Affiliates and licensees, and their respective directors, officers, employees, and agents (the “Customer Indemnitees”) from and against any
claims, suits, actions, or proceedings brought by a Third Party (collectively, “Claims”) against any Customer Indemnitee, as well as any liabilities, damages, or recoveries payable to a Third Party claimant and any reasonable
attorneys’ fees and costs of litigation incurred by a Customer Indemnitee in connection therewith, to the extent resulting from or arising out of (a) Supplier’s breach of any warranty or other provision of the Agreement; (b) the
negligence or intentional misconduct of Supplier, its employees, officers, agents or representatives; or (c) any claim that alleges that any process or machinery utilized by Supplier in manufacturing and/or supplying Product hereunder infringes
upon, misappropriates or violates any laws or any intellectual property rights of any Third Party, except in each case to the extent resulting from the negligence or willful misconduct of any Customer Indemnitee or Customer’s breach of this
Agreement. 
 7.2 Customer Indemnity. Customer shall indemnify, hold harmless, and defend Supplier and its Affiliates, and their
respective directors, officers, employees, and agents (the “Supplier Indemnitees”) from and against any Claims against any Supplier Indemnitee, as well as any liabilities, damages, or recoveries payable to a Third Party claimant and
any reasonable attorneys’ fees and costs of litigation incurred by a Customer Indemnitee in connection therewith, to the extent resulting from or arising out of (a) Customer’s breach of any warranty or other provision of the
Agreement; or (b) the negligence or intentional misconduct of Customer, its employees, officers, agents or representatives, except in each case to the extent caused by the negligence or willful misconduct of any Supplier Indemnitee or
Supplier’s breach of this Agreement. 
 7.3 Indemnification Procedures. In the event of any Claim that may be subject to
indemnification under this Article 7, the indemnified Party shall: (a) promptly notify the indemnifying Party of such Claim; (b) at the indemnifying Party’s expense, reasonably cooperate with the indemnifying Party in the defense of
such Claim; and (c) not settle any such Claim without the indemnifying Party’s 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
written consent, which shall not be unreasonably withheld or delayed. The indemnifying Party shall keep the indemnified Party informed at all times as to the status of the indemnifying
Party’s efforts and consult with the indemnified Party and/or its counsel regarding such efforts. The indemnifying Party shall not settle any such Claim in any manner that negatively impacts the rights of the indemnified Party or any other
indemnitee without the prior written consent of the indemnified Party. The indemnified Party may participate in proceedings relating to any indemnified Claim with counsel of its own choosing at its own expense. 

7.4 Insurance. Reference Exhibit C, Certificate of Liability Insurance. 

ARTICLE 8 

CONFIDENTIALITY 
 8.1
Confidentiality Obligation. During the term of this Agreement, and for seven (7) years thereafter, each Party shall maintain in confidence any and all Confidential Information of the other Party, except as set forth in Section 8.2
below. Each Party further agrees that it shall not use for any purpose other than the purposes expressly permitted or contemplated under this Agreement, and shall not disclose to any Third Party, the Confidential Information of the other Party,
except that either Party may disclose Confidential Information on a need-to-know basis to its directors, officers, employees, consultants, or agents who are subject to written obligations of confidentiality and non-use that are no less restrictive
than those set forth herein. Upon termination or expiration of the Agreement, or upon written request of the other Party, a Party will promptly return to the other Party, or destroy, all documents, notes and other tangible materials representing the
Confidential Information of such other Party and all copies thereof; provided, however, that such other Party may retain a single archival copy of the Confidential Information for the sole purpose of facilitating compliance with the surviving
provisions of this Agreement. 
 8.2 Exceptions. The obligations of confidentiality and non-use contained in Section 8.1 shall
not apply to any information to the extent that it can be established by the Party receiving the information (the “Receiving Party”) that such information: (a) was already known to the Receiving Party, other than under an
obligation of confidentiality, at the time of disclosure by the other Party; (b) was part of the public domain at the time of its disclosure to the Receiving Party or became part of the public domain after its disclosure to the Receiving Party
through no fault of the Receiving Party; (c) was disclosed to the Receiving Party, other than under an obligation of confidentiality, by a Third Party who had no obligation to the disclosing Party not to disclose such information to others; or
(d) was independently discovered or developed by the Receiving Party without the use of or access to Confidential Information of the disclosing Party. 

8.3 Authorized Disclosure. Each Party may disclose Confidential Information of the other Party to the extent such disclosure is
reasonably necessary in complying with applicable laws, including securities laws, governmental regulations or court orders, and obtaining regulatory or other government approvals, provided that a Party making any such disclosure uses its reasonable
efforts to secure confidential treatment of such Confidential Information required to be disclosed and to minimize the extent of such disclosure. 

8.4 Publicity. Supplier shall not make any announcement or other public statement concerning the existence or terms of this Agreement,
or the activities conducted under this Agreement, without the prior written consent of Customer, except as required by applicable law. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 8.5 Injunctive Relief. The Parties expressly acknowledge and agree that any breach or
threatened breach of this Article 8 by the Receiving Party may cause immediate and irreparable harm to the other Party which may not be adequately compensated by damages. Each Party therefore agrees that in the event of such breach or threatened
breach and in addition to any remedies available at law, each Party shall have the right to secure equitable and injunctive relief, without bond, in connection with such a breach or threatened breach. 

ARTICLE 9 
 INTELLECTUAL
PROPERTY 
 9.1 Existing Intellectual Property. Subject to Sections 9.2 and 9.3, each Party shall retain all rights in all
intellectual property rights owned or controlled by such Party prior to the Effective Date or developed or acquired by such Party during the term of this Agreement. 

9.2 License. The purchase of the Products shall confer on Customer and its Affiliates, and their respective subcontractors,
distributors and agents, an irrevocable, world-wide, royalty-free, non-exclusive, non transferable license under Supplier’s patent applications, patents, copyrights, trade secrets, trademarks or other intellectual property rights it owns or
controls, to use, test, market, sell, lease, distribute or otherwise dispose of such Products and to incorporate such Products into Customer’s products, as well as to convey to their respective customers a right to use any such Products that
are sold to such customers under such license. 
 9.3 Inventions. Customer shall own all right, title, and interest in and to
any and all ideas, inventions, processes, methods, or improvements (whether patentable or unpatentable) that are developed solely or jointly by Supplier at Customer’s request or specifically for use by Customer and not for general use by
Supplier with its other customers relating to the Products and that arise out of the work performed under this Agreement, along with all intellectual property rights with respect thereto (collectively, the “Inventions”). Supplier
agrees to communicate all Inventions promptly to Customer. Supplier hereby assigns and transfers to Customer all right, title and interest in and to the Inventions and agrees to take all further acts reasonably required to evidence such assignment
and transfer to Customer, at Customer’s expense. Supplier shall enter into an agreement with each employee or agent of Supplier performing work in connection with the manufacture and supply of Product hereunder, pursuant to which such person
assigns all rights in the Inventions to Supplier such that Supplier may assign and transfer such rights to Customer in accordance with this Section 9.3. Supplier hereby appoints Customer as its attorney-in-fact to sign such documents as
Customer deems necessary for Customer to obtain ownership and to apply for, secure, and maintain patent or other proprietary protection of Inventions if Customer is unable, after reasonable inquiry, to obtain Supplier’s (or its employee’s
or agent’s) signature on such a document. All Inventions and any information with respect thereto shall be Customer’s Confidential Information subject to the confidentiality provisions of Article 8. 

ARTICLE 10 
 TERM AND
TERMINATION 
 10.1 Term. This Agreement shall commence on the Effective Date and shall continue in effect for one (1) year
thereafter, unless earlier terminated as permitted under this Article 10 (the “Initial Term”). This Agreement will automatically renew for successive one (1) year terms, unless a Party provided written notice of non-renewal to
the other Party not less than thirty (30) days prior to the end of the then-current term.  

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 10.2 Material Breach. Either Party shall have the right to terminate this Agreement upon
written notice to the other Party if the other Party commits any material breach of this Agreement that such breaching Party fails to cure within thirty (30) days following written notice from the nonbreaching Party specifying such breach. 

10.3 Change of Control of Supplier. Supplier shall notify Customer promptly upon the earlier of (a) public announcement of the
entry into an agreement providing for a Change of Control of Supplier or (b) Change of Control of Supplier. Thereafter, Customer may terminate this Agreement upon twelve (12) months written notice to Supplier. During such notice period,
Supplier shall provide assistance as reasonably requested by Customer to adopt an alternative supplier until such time as Customer receives FDA approval to implement any applicable changes. 

10.4 Surviving Obligations. Except for any purchase orders submitted pursuant to Section 10.6, all purchase orders for Product
that are outstanding on the date this Agreement terminates or expires, for any reason, shall be deemed automatically terminated as of the effective date of such termination or expiration. Termination or expiration of this Agreement shall not affect
any other rights or liabilities of either Party which may have accrued up to the date of such termination or expiration. The provisions of Sections 3.1, 3.2, 4.1, 4.5, 10.5, 10.6, 11.2, 11.3, 11.5, 11.9 and 11.12 and Articles 1, 7, 8 and 9 shall
survive the termination or expiration of this Agreement. 
 10.5 Customer’s Last-Time Buy Rights. During the thirty
(30) days immediately prior to the expiration of this Agreement pursuant to Section 10.1, or in the event that the Parties mutually agree to terminate the Agreement, or in the event of Product discontinuance, Customer may in its sole
discretion submit a single order for Products, which order shall be deemed accepted by Supplier to the extent the number of units of Products so ordered does not exceed, [*]. Supplier shall satisfy any such order as soon as reasonably practicable,
and in any event Supplier shall deliver [*] of the number of units of Products ordered pursuant to this Section 10.6 over a period no longer than [*] after the date of such order and shall deliver all Products ordered pursuant to this
Section 10.6 over a period no longer than [*] after the date of such order. 
 ARTICLE 11 

GENERAL TERMS 
 11.1
Use of Name. No right, express or implied, is granted by this Agreement to either Party to use in any manner the name of the other or any other trade name or trademark of the other in connection with the performance of this Agreement.

 11.2 Recall. In the event that Customer decides or is required to recall any Product, to take any corrective action with
respect to any Product, or to disseminate safety information regarding any Product, Customer shall so notify Supplier. Promptly, but in no event later than may be required to permit Customer to meet applicable legal or regulatory requirements,
Supplier shall provide Customer with such assistance in connection with such recall, corrective action, or dissemination of information as may reasonably be requested by Customer. If Customer effects any such recall, corrective action, or
dissemination of information involving a Product purchased hereunder, and such recall, corrective action, or dissemination of information was caused by a Defective Product provided by Supplier, or otherwise was related to matters that constitute a
breach of Supplier’s warranty covering such Product under Section 6.3, then Supplier shall [*]. Reference such products identified in Exhibit A. 

11.3 LIMITATION OF LIABILITY. NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, PUNITIVE, OR
INDIRECT  

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
DAMAGES ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT OR ANY TORT CLAIMS ARISING HEREUNDER, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. NOTWITHSTANDING THE FOREGOING,
NOTHING IN THIS PARAGRAPH IS INTENDED TO LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY UNDER ARTICLE 7 OR DAMAGES AVAILABLE FOR BREACHES OF ARTICLE 8. 

11.4 Independent Parties. The Parties are not employees or legal representatives of each other for any purpose. Neither Party shall
have the authority to enter into any contracts in the name of or on behalf of the other Party. 
 11.5 Notice. All notices,
including notices of address change, required or permitted to be given under this Agreement shall be in writing and deemed to have been received (a) when received if hand delivered, (b) four (4) days after being sent by first class
U.S. mail, postage prepaid, or (c) one (1) business day after being sent by an internationally recognized overnight delivery service, in each case addressed to, in the case of Customer, Felicia Mercado, and in the case of Supplier, Debi
Metcalf, in each case at the address of the relevant Party first set forth above. 
 11.6 Severability. In the event any provision of
this Agreement is held to be invalid or unenforceable, the valid or enforceable portion thereof and the remaining provisions of this Agreement will remain in full force and effect. 

11.7 Waiver. Any waiver (express or implied) by either Party of any breach of this Agreement shall not constitute a waiver of any other
or subsequent breach. 
 11.8 Entire Agreement; Amendment. This Agreement, the Quality Agreement and the exhibits attached
hereto constitute the entire, final, complete and exclusive agreement between the Parties and supersede all previous agreements or representations, written or oral, with respect to the subject matter of this Agreement, including without limitation
the [Confidential Disclosure Agreement between the Parties dated 1/28/14.] All information to be kept confidential under such earlier confidentiality agreement as of the Effective Date shall be maintained as Confidential Information by
the receiving Party under the obligations set forth in Article 8 of this Agreement. This Agreement may not be modified or amended except in a writing signed by a duly authorized representative of each Party. 

11.9 Nonassignability; Binding on Successors. Any attempted assignment of the rights or delegation of the obligations under this
Agreement shall be void without the prior written consent of the nonassigning or nondelegating Party; provided, however, that Customer may assign its rights or delegate its obligations under this Agreement without such consent (i) to an
Affiliate of Customer or (ii) to its successor in interest in connection with any merger, consolidation, or sale of all or substantially all of the assets of Customer to which this Agreement relates. This Agreement shall be binding upon, and
inure to the benefit of, the successors, executors, heirs, representatives, administrators and permitted assigns of the Parties hereto, and any successor to Supplier shall agree in writing to be so bound and to supply Customer’s requirements of
Products under the terms of this Agreement. 
 11.10 Force Majeure. Neither Party shall be liable to the other for its failure
to perform any of its obligations under this Agreement during any period in which such performance is delayed because rendered impracticable or impossible due to circumstances beyond its reasonable control, including earthquakes, governmental
regulation, fire, flood, labor difficulties, civil disorder, and acts of God, provided that the Party experiencing the delay promptly notifies the other Party of the delay and uses commercially reasonable efforts to overcome such circumstances.

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 11.11 Conflict of Terms. In the event of a conflict between the terms of this Agreement
and the terms of the Exhibits attached hereto, the terms of this Agreement shall govern. 
 11.12 Governing Law. Any claim,
dispute, or controversy of whatever nature arising out of or relating to this Agreement shall be governed by and construed under the laws of the State of California, without giving effect to any choice of law principles that would require the
application of the laws of a different state or country. 
 11.13 Counterparts. This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original and all of which shall constitute together the same instrument. 

IN WITNESS WHEREOF, the Parties hereto have duly executed this Agreement on the Effective
Date. 
  

									
	INTERSECT ENT, INC.	 		 	AIM PLASTICS
					
	By:	 	 /s/ Rich Kaufman
	 		 	By:	 	 /s/ Craig Fisher

									
	Name:	 	Rich Kaufman	 		 	Name:	 	Craig Fisher
	Title:	 	Chief Operating Officer	 		 	Title:	 	President

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 EXHIBIT A 

PRODUCTS/ PRICE LIST 

 

					
	 Part number & Description
	  	 Price per Unit

Quote #41-31.R
	 	 2014 Annual

Forecast

	 [*]
	  	[*]	 	[*]
	 [*]
	  	[*]	 	[*]
	 [*]
	  	[*]	 	[*]
	 [*]
	  	[*]	 	[*]
	 [*]
	  	[*]	 	[*]
	 [*]
	  	[*]	 	[*]
	 [*]
	  	[*]	 	[*]
	 [*]
	  	[*]	 	[*]
	 [*]
	  	[*]	 	[*]
	 [*]
	  	[*]	 	[*]
	 [*]
	  	[*]	 	[*]

 NEW PRICING EFFECTIVE UPON IMPLEMENTATION
OF NEW TOOLING 
  

					
	 Part number and Name
	  	 Price per Unit
	 	 Tooling PO

	 [*]
	  	[*]	 	[*]
	 [*]
	  	[*]	 	[*]
	 [*]
	  	[*]	 	[*]

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 EXHIBIT B 

SPECIFICATIONS 
 Relevant
component specifications shall be attached to applicable purchase order at time issuance. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 EXHIBIT C 

Certificate of Liability Insurance 
 [*] 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}]]